Office of the Secretary, Muscular Dystrophy Coordinating Committee Call for Committee Membership Nominations, 34259-34260 [2024-09303]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 84 / Tuesday, April 30, 2024 / Notices
Contact Person: Andrea B. Kelly, Ph.D.,
Scientific Review Officer, National Institute
on Deafness and Other Communication
Disorders, National Institutes of Health, 6001
Executive Boulevard, Room 8351, Bethesda,
MD 20892, (301) 451–6339, kellya2@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
Dated: April 24, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–09180 Filed 4–29–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; NIA IMPACT
Collaboratory.
Date: June 7, 2024.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sandhya Sanghi, Ph.D.,
Scientific Review Officer, National Institutes
of Health,National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue
(2N230), NIA/SRB, Bethesda, MD 20892,
(301) 496–2879, sandhya.sanghi@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: April 25, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–09261 Filed 4–29–24; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:27 Apr 29, 2024
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Allergy, Immunology,
and Transplantation Research Committee.
Date: June 20–21, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G51,
Rockville, MD 20892 (Virtual).
Contact Person: Thomas F. Conway, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G51, Rockville, MD
20892, 240–507–9685, thomas.conway@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: April 25, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–09302 Filed 4–29–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Advisory
Council on Drug Abuse, May 07, 2024,
10:30 a.m. to May 07, 2024, 05:00 p.m.,
National Institutes of Health,
Neuroscience Center, 6001 Executive
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
34259
Boulevard, Rockville, MD 20852 which
was published in the Federal Register
on March 28, 2024, FR Doc. 2024–
06612, 89 FR 21526.
This notice is being amended to
change the open session start and end
time from 12:45 p.m.–05:00 p.m. to
01:00 p.m.–4:45 p.m. The meeting date,
closed session time, and location will
stay the same. The meeting is partially
closed to the public.
Dated: April 25, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–09260 Filed 4–29–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Secretary, Muscular
Dystrophy Coordinating Committee
Call for Committee Membership
Nominations
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Office of the Secretary of
the Department of Health and Human
Services (HHS) is seeking nominations
for one individual to serve as a nonFederal public member on the Muscular
Dystrophy Coordinating Committee.
DATES: Nominations are due by 5:00
p.m. ET on May 31, 2024.
ADDRESSES: Nominations must be sent
to Glen Nuckolls, Ph.D., by email to
nuckollg@ninds.nih.gov.
FOR FURTHER INFORMATION CONTACT: Glen
Nuckolls, Ph.D., by email to nuckollg@
ninds.nih.gov or (301) 496–5745.
SUPPLEMENTARY INFORMATION: The
Muscular Dystrophy Coordinating
Committee (MDCC) is a Federal
advisory committee established in
accordance with the Muscular
Dystrophy Community Assistance,
Research, and Education Amendments
of 2001 (MD–CARE Act; Pub. L. 107–
84). The MD–CARE Act was
reauthorized in 2008 by Public Law
110–361, and again in 2014 by Public
Law 113–166. The MD–CARE Act
specifies that the committee
membership be composed of 2⁄3
governmental agency representatives
and 1⁄3 public members. We are seeking
nominations for one non-Federal public
member at this time, due to turnover of
committee membership. Nominations
will be accepted until 5:00 p.m. ET on
May 31, 2024.
SUMMARY:
E:\FR\FM\30APN1.SGM
30APN1
lotter on DSK11XQN23PROD with NOTICES1
34260
Federal Register / Vol. 89, No. 84 / Tuesday, April 30, 2024 / Notices
Who is Eligible: Nominations are
encouraged for new or reappointment of
non-Federal public members who can
provide the public and/or patient
perspectives to discussions of issues
considered by the Committee. Selfnominations and nominations of other
individuals are both permitted. Only
one nomination per individual is
required. Multiple nominations for the
same individual will not increase
likelihood of selection. Non-Federal
public members may be selected from
the pool of submitted nominations or
other sources as needed to meet
statutory requirements and to form a
balanced committee that represents the
diversity within the muscular dystrophy
communities. Nominations are
especially encouraged from leaders or
representatives of muscular dystrophy
research, advocacy, or service
organizations, as well as individuals
with muscular dystrophy or their
parents or guardians. In accordance
with White House Office of
Management and Budget guidelines (FR
Doc. 2014–19140), federally-registered
lobbyists are not eligible.
Committee Composition: The
Department strives to ensure that the
membership of HHS Federal advisory
committees is fairly balanced in terms of
points of view represented and the
committee’s function. Every effort is
made to ensure that the views of all
genders, all ethnic and racial groups,
and people with disabilities are
represented on HHS Federal advisory
committees and, therefore, the
Department encourages nominations of
qualified candidates from these groups.
The Department also encourages
geographic diversity in the composition
of the Committee. Appointment to this
Committee shall be made without
discrimination on the basis of age, race,
ethnicity, gender, sexual orientation,
disability, and cultural, religious, or
socioeconomic status. Requests for
reasonable accommodation to enable
participation on the Committee should
be indicated in the nomination
submission.
Member Terms: Non-Federal public
members of the Committee serve for a
term of three years and may serve for an
unlimited number of terms if
reappointed. Members may serve after
the expiration of their terms, until their
successors have taken office.
Meetings and Travel: As specified by
Public Law 113–166, the MDCC ‘‘shall
meet no fewer than two times per
calendar year.’’ Travel expenses are
provided for non-Federal public
Committee members to facilitate
attendance at in-person meetings.
Members are expected to make every
VerDate Sep<11>2014
17:27 Apr 29, 2024
Jkt 262001
effort to attend all full committee
meetings, twice per year, either in
person or via remote access.
Participation in relevant subcommittee,
working and planning group meetings,
and workshops, is also encouraged.
Submission Instructions and
Deadline: Nominations are due by 5:00
p.m. ET on May 31, 2024, and should
be sent to Glen Nuckolls, Ph.D., by
email to nuckollg@ninds.nih.gov.
Nominations must include contact
information for the nominee, a current
curriculum vitae or resume of the
nominee, and a paragraph describing
the qualifications of the person to
represent some portion(s) of the
muscular dystrophy research, advocacy,
and/or patient care communities.
More information about the MDCC is
available at https://mdcc.nih.gov/.
Dated: April 24, 2024.
Walter J. Koroshetz,
Director, National Institute of Neurological
Disorders and Stroke, National Institutes of
Health.
[FR Doc. 2024–09303 Filed 4–29–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Dementia
Caregiver Support Intervention.
Date: May 24, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sandhya Sanghi, Ph.D.,
Scientific Review Officer, National Institutes
of Health, National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue
(2N230), NIA/SRB, Bethesda, MD 20892,
(301) 496–2879, sandhya.sanghi@nih.gov.
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
Name of Committee: National Institute on
Aging Special Emphasis Panel; NIA multisite
clinical trials.
Date: May 31, 2024.
Time: 9:30 a.m. to 11:00 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Maurizio Grimaldi, M.D.,
Ph.D., Scientific Review Officer, National
Institutes of Health, National Institute on
Aging, Gateway Building, 7201 Wisconsin
ROOM 2C218, Bethesda, MD 20892, 301–
496–9374, grimaldim2@mail.nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Validation of
Analytical and Clinical Biomarkers for
ADRD.
Date: June 20, 2024.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Gianina Ramona
Dumitrescu, MPH, Ph.D., Scientific Review
Officer, National Institutes of Health,
National Institute on Aging, Gateway
Building, 7201 Wisconsin ROOM 2C218,
Bethesda, MD 20892, 301–827–4342,
ramona.dumitrescu@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: April 24, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–09179 Filed 4–29–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
[OMB Control Number 1651–0123]
Agency Information Collection
Activities; Revision; Regulations
Relating to Copyrights and
Trademarks
U.S. Customs and Border
Protection (CBP), Department of
Homeland Security.
ACTION: 30-Day notice and request for
comments.
AGENCY:
The Department of Homeland
Security, U.S. Customs and Border
Protection (CBP) will be submitting the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995 (PRA). The
information collection is published in
SUMMARY:
E:\FR\FM\30APN1.SGM
30APN1
]]>Agencies
[Federal Register Volume 89, Number 84 (Tuesday, April 30, 2024)]
[Notices]
[Pages 34259-34260]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-09303]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Secretary, Muscular Dystrophy Coordinating
Committee Call for Committee Membership Nominations
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Office of the Secretary of the Department of Health and
Human Services (HHS) is seeking nominations for one individual to serve
as a non-Federal public member on the Muscular Dystrophy Coordinating
Committee.
DATES: Nominations are due by 5:00 p.m. ET on May 31, 2024.
ADDRESSES: Nominations must be sent to Glen Nuckolls, Ph.D., by email
to [email protected].
FOR FURTHER INFORMATION CONTACT: Glen Nuckolls, Ph.D., by email to
[email protected] or (301) 496-5745.
SUPPLEMENTARY INFORMATION: The Muscular Dystrophy Coordinating
Committee (MDCC) is a Federal advisory committee established in
accordance with the Muscular Dystrophy Community Assistance, Research,
and Education Amendments of 2001 (MD-CARE Act; Pub. L. 107-84). The MD-
CARE Act was reauthorized in 2008 by Public Law 110-361, and again in
2014 by Public Law 113-166. The MD-CARE Act specifies that the
committee membership be composed of \2/3\ governmental agency
representatives and \1/3\ public members. We are seeking nominations
for one non-Federal public member at this time, due to turnover of
committee membership. Nominations will be accepted until 5:00 p.m. ET
on May 31, 2024.
[[Page 34260]]
Who is Eligible: Nominations are encouraged for new or
reappointment of non-Federal public members who can provide the public
and/or patient perspectives to discussions of issues considered by the
Committee. Self-nominations and nominations of other individuals are
both permitted. Only one nomination per individual is required.
Multiple nominations for the same individual will not increase
likelihood of selection. Non-Federal public members may be selected
from the pool of submitted nominations or other sources as needed to
meet statutory requirements and to form a balanced committee that
represents the diversity within the muscular dystrophy communities.
Nominations are especially encouraged from leaders or representatives
of muscular dystrophy research, advocacy, or service organizations, as
well as individuals with muscular dystrophy or their parents or
guardians. In accordance with White House Office of Management and
Budget guidelines (FR Doc. 2014-19140), federally-registered lobbyists
are not eligible.
Committee Composition: The Department strives to ensure that the
membership of HHS Federal advisory committees is fairly balanced in
terms of points of view represented and the committee's function. Every
effort is made to ensure that the views of all genders, all ethnic and
racial groups, and people with disabilities are represented on HHS
Federal advisory committees and, therefore, the Department encourages
nominations of qualified candidates from these groups. The Department
also encourages geographic diversity in the composition of the
Committee. Appointment to this Committee shall be made without
discrimination on the basis of age, race, ethnicity, gender, sexual
orientation, disability, and cultural, religious, or socioeconomic
status. Requests for reasonable accommodation to enable participation
on the Committee should be indicated in the nomination submission.
Member Terms: Non-Federal public members of the Committee serve for
a term of three years and may serve for an unlimited number of terms if
reappointed. Members may serve after the expiration of their terms,
until their successors have taken office.
Meetings and Travel: As specified by Public Law 113-166, the MDCC
``shall meet no fewer than two times per calendar year.'' Travel
expenses are provided for non-Federal public Committee members to
facilitate attendance at in-person meetings. Members are expected to
make every effort to attend all full committee meetings, twice per
year, either in person or via remote access. Participation in relevant
subcommittee, working and planning group meetings, and workshops, is
also encouraged.
Submission Instructions and Deadline: Nominations are due by 5:00
p.m. ET on May 31, 2024, and should be sent to Glen Nuckolls, Ph.D., by
email to [email protected]. Nominations must include contact
information for the nominee, a current curriculum vitae or resume of
the nominee, and a paragraph describing the qualifications of the
person to represent some portion(s) of the muscular dystrophy research,
advocacy, and/or patient care communities.
More information about the MDCC is available at https://mdcc.nih.gov/.
Dated: April 24, 2024.
Walter J. Koroshetz,
Director, National Institute of Neurological Disorders and Stroke,
National Institutes of Health.
[FR Doc. 2024-09303 Filed 4-29-24; 8:45 am]
BILLING CODE 4140-01-P
